纳武单抗治疗铂难治性不可切除的局部晚期头颈部鳞状细胞癌:1例报告和文献综述

M.S. Ruban, L.V. Bolotina
{"title":"纳武单抗治疗铂难治性不可切除的局部晚期头颈部鳞状细胞癌:1例报告和文献综述","authors":"M.S. Ruban,&nbsp;L.V. Bolotina","doi":"10.1016/j.oor.2025.100725","DOIUrl":null,"url":null,"abstract":"<div><div>Head and neck squamous cell carcinoma (HNSCC) is associated with high mortality and poses a significant public health challenge. Platinum-based chemotherapy is a primary treatment modality; however, the median survival for patients experiencing recurrence within six months of platinum-based therapy is no more than six months. Immune checkpoint inhibitors, such as nivolumab and pembrolizumab, have revolutionized the treatment of platinum-refractory HNSCC since their FDA approval in 2016. This case report highlights the successful use of nivolumab in a patient with platinum-refractory, unresectable HNSCC, achieving long-term survival of over six years. The patient demonstrated a significant tumor reduction and stabilization of disease, followed by successful surgical management of recurrent lymph node growth. This case underscores the potential for durable responses with nivolumab, even in the absence of PD-L1 testing, and highlights the integration of immunotherapy with surgery as a personalized treatment strategy. The findings contribute to the growing body of real-world evidence supporting the use of immune checkpoint inhibitors in platinum-refractory HNSCC.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100725"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nivolumab in platinum-refractory unresectable locally advanced squamous cell carcinoma of the head and neck: A case report and literature review\",\"authors\":\"M.S. Ruban,&nbsp;L.V. Bolotina\",\"doi\":\"10.1016/j.oor.2025.100725\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Head and neck squamous cell carcinoma (HNSCC) is associated with high mortality and poses a significant public health challenge. Platinum-based chemotherapy is a primary treatment modality; however, the median survival for patients experiencing recurrence within six months of platinum-based therapy is no more than six months. Immune checkpoint inhibitors, such as nivolumab and pembrolizumab, have revolutionized the treatment of platinum-refractory HNSCC since their FDA approval in 2016. This case report highlights the successful use of nivolumab in a patient with platinum-refractory, unresectable HNSCC, achieving long-term survival of over six years. The patient demonstrated a significant tumor reduction and stabilization of disease, followed by successful surgical management of recurrent lymph node growth. This case underscores the potential for durable responses with nivolumab, even in the absence of PD-L1 testing, and highlights the integration of immunotherapy with surgery as a personalized treatment strategy. The findings contribute to the growing body of real-world evidence supporting the use of immune checkpoint inhibitors in platinum-refractory HNSCC.</div></div>\",\"PeriodicalId\":94378,\"journal\":{\"name\":\"Oral Oncology Reports\",\"volume\":\"13 \",\"pages\":\"Article 100725\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Oncology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772906025000135\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Oncology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772906025000135","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

头颈部鳞状细胞癌(HNSCC)与高死亡率相关,对公共卫生构成重大挑战。以铂类为主的化疗是主要的治疗方式;然而,在铂类药物治疗6个月内复发的患者的中位生存期不超过6个月。免疫检查点抑制剂,如nivolumab和pembrolizumab,自2016年获得FDA批准以来,已经彻底改变了铂难治HNSCC的治疗。本病例报告强调了在铂难治、不可切除的HNSCC患者中成功使用nivolumab,实现了超过6年的长期生存。患者表现出明显的肿瘤缩小和疾病稳定,随后成功的手术治疗复发性淋巴结生长。该病例强调了即使在缺乏PD-L1测试的情况下,nivolumab也有可能产生持久的反应,并强调了将免疫治疗与手术相结合作为个性化治疗策略。这些发现为越来越多的实际证据支持免疫检查点抑制剂在铂难治的HNSCC中的应用做出了贡献。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Nivolumab in platinum-refractory unresectable locally advanced squamous cell carcinoma of the head and neck: A case report and literature review
Head and neck squamous cell carcinoma (HNSCC) is associated with high mortality and poses a significant public health challenge. Platinum-based chemotherapy is a primary treatment modality; however, the median survival for patients experiencing recurrence within six months of platinum-based therapy is no more than six months. Immune checkpoint inhibitors, such as nivolumab and pembrolizumab, have revolutionized the treatment of platinum-refractory HNSCC since their FDA approval in 2016. This case report highlights the successful use of nivolumab in a patient with platinum-refractory, unresectable HNSCC, achieving long-term survival of over six years. The patient demonstrated a significant tumor reduction and stabilization of disease, followed by successful surgical management of recurrent lymph node growth. This case underscores the potential for durable responses with nivolumab, even in the absence of PD-L1 testing, and highlights the integration of immunotherapy with surgery as a personalized treatment strategy. The findings contribute to the growing body of real-world evidence supporting the use of immune checkpoint inhibitors in platinum-refractory HNSCC.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.20
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信